Biopharmaceutical company specializing on psychedelic drug development, unique delivery mechanisms, improved novel compounds and protocols Cybin Inc. (NYSE: CYBN) announced been awarded a notice of allowance by the United States Patent and Trademark Office (USPTO) for patent application no. 17/394,038 related to CYB004.
CYB004 is Cybin’s investigational deuterated psychedelic tryptamine compound used as a potential treatment for anxiety disorder. The allowed claims also include other forms of deuterated psychedelic tryptamine plus some certain deuterated forms of DMT and 5-MeO-DMT.
Citing records from United States National institute of Mental Health, anxiety disorders and other common mental conditions approximately affect 40 million people annually roughly representing 18% of the country’s entire population.
The patent in question covers composition of matter for the CYB004 drug substance as a putative new chemical entity. The patent is scheduled to expire on 2041 prior to any considerations of any term extensions.
“The receipt of this Notice of Allowance from the USPTO represents an important milestone in expanding our intellectual property portfolio progressing psychedelics to therapeutics for the countless patients in need, and strongly demonstrates the Company’s dedication to the discovery and development of differentiated psychedelic-based compounds for addressing mental health. Once issued, this patent may have the opportunity to cover a broad range of claims supporting our IP in psychedelic medicine and further strengthen our emerging best-in-class position in this evolving industry,” said the company’s CEO, Doug Drysdale.
